Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FOCUS: An Open Label First in Human Phase I/II Multicentre Study to Evaluate the Safety, Dose Response and Efficacy of GT005 Administered as a Single Subretinal Injection in Subjects With Macular Atrophy Due to AMD

NCT03846193 is registered in ClinicalTrials.gov with Gyroscope Therapeutics Limited as lead sponsor.

NCT NCT03846193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03846193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FOCUS: An Open Label First in Human Phase I/II Multicentre Study to Evaluate the Safety, Dose Response and Efficacy of GT005 Administered as a Single Subretinal Injection in Subjects With Macular Atrophy Due to AMD
Lead sponsor
Gyroscope Therapeutics Limited
Phase
Phase 1/2
Overall status
Terminated
Start date
December 17, 2018
Completion date
June 25, 2024
Enrollment
56 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

dry age-related macular degeneration, eye diseases, geographic atrophy, macular atrophy, macular degeneration, retinal degeneration, retinal disease